Lack of CD8 + T cell effector differentiation during priming mediates checkpoint blockade resistance in non–small cell lung cancer-Reference-Cited by-同舟云学术

Lack of CD8 + T cell effector differentiation during priming mediates checkpoint blockade resistance in non–small cell lung cancer

Published:2021-10-29 Issue:64 Volume:6 Page:
ISSN:2470-9468
Container-title:Science Immunology
language:en
Short-container-title:Sci. Immunol.

Author:

Horton Brendan L.¹^ORCID,Morgan Duncan M.¹²^ORCID,Momin Noor¹³^ORCID,Zagorulya Maria¹⁴^ORCID,Torres-Mejia Elen¹^ORCID,Bhandarkar Vidit¹⁴,Wittrup K. Dane¹²³^ORCID,Love J. Christopher¹²⁵^ORCID,Spranger Stefani¹⁴⁵^ORCID

Affiliation:

1. Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA.

2. Department of Chemical Engineering, MIT, Cambridge, MA, USA.

3. Department of Biological Engineering, MIT, Cambridge, MA, USA.

4. Department of Biology, MIT, Cambridge, MA, USA.

5. Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.

Abstract

A lung cancer–specific form of CD8 + T cell dysfunction is established during T cell priming and contributes to ICB resistance.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine,Immunology

Reference89 articles.

1. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

2. Immune-based Therapies for Non-small Cell Lung Cancer

3. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

4. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

5. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expansion of tumor-reactive CD8 ⁺ T cell clonotypes occurs in the spleen in response to immune checkpoint blockade;Science Immunology;2024-09-13

2. Bacterial and cancerous cell membrane fused liposome coordinates with PD-L1 inhibitor for cancer immunotherapy;Nano Research;2024-08-03

3. Fractalkine in Health and Disease;International Journal of Molecular Sciences;2024-07-23

4. CIMT 2024: Report on the 21st Annual Meeting of the Association for Cancer Immunotherapy;Human Vaccines & Immunotherapeutics;2024-07-23

5. YTH domain family protein 3 accelerates non-small cell lung cancer immune evasion through targeting CD8+ T lymphocytes;Cell Death Discovery;2024-07-11